May Health Raises $11.7M in Funding to Advance PCOS Medical Device Platform

May Health just pulled in $11.7M in financing and if you follow women’s health innovation closely, you know this is the kind of signal that travels further than the headline. The Paris and Menlo Park-based clinical stage medical device company is chasing one of reproductive medicine’s most stubborn challenges, and the capital moving in around them suggests the industry is paying attention.

Credit where it is due. Congratulations to CEO Colby Holtshouse and the entire May Health team, along with original founders Neil Barman, Andy Wu, and Garrett Schwab who set this story in motion back in 2012 when the company began life as Ziva Medical. Startups evolve the way good jazz does. A few tempo changes, a rebrand or two, and suddenly the sound gets sharper. Ziva Medical became Ablacare, and in 2022 the company stepped into its current identity as May Health, focused squarely on one of reproductive medicine’s most persistent challenges.

Polycystic ovary syndrome affects about 10% of women and remains one of the leading causes of infertility. That is not a niche problem. That is a global medical conversation waiting for better tools. May Health’s answer is something called Ovarian Rebalancing. A one time, office based, transvaginal ablation procedure designed with a simple ambition that carries enormous weight. Restore ovulation in women with PCOS related infertility.

If you spend enough time around fertility clinics and reproductive medicine, you learn something quickly. Most solutions involve ongoing treatments, cycles, and complicated paths. May Health is exploring something different. A single procedure designed to address the underlying imbalance. Not louder medicine. Smarter medicine.

The capital behind this round tells its own story. Returning investors Sofinnova Partners, Trill Impact, and Bpifrance stepped back into the arena, joined by Nexpring Health, a global ART solutions company entering the mix as a new investor. When experienced healthcare investors double down while a strategic player pulls up a chair, it usually means one thing. The underlying science and clinical direction have real gravity.

This funding will help push forward the REBALANCE IDE clinical trial in the United States, an important step toward potential FDA marketing authorization. Clinical stage medtech is a marathon, not a sprint. Evidence matters. Trials matter. Execution matters even more.

There is also a quiet business lesson humming beneath the surface here. May Health did not sprint to headlines. The company built through stages. Founders planted the seed. Sofinnova MD Start helped accelerate development after the 2017 acquisition. Leadership evolved. Capital followed progress. In venture terms, that rhythm is called trust compounding.

Women’s health has long been an underfunded frontier in medical innovation. That tide is shifting. When technology, capital, and clinical focus align around real unmet needs, momentum has a way of showing up like spring after a long winter. For May Health, the name might be doing a little forecasting.